カテゴリ： GlobalData, アメリカ, 企業調査

XBiotech Inc (XBIT)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：XBiotech Inc (XBIT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C8172
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：57
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
XBiotech Inc (XBiotech) is a biopharmaceutical company that discovers, develops and commercialize therapeutic antibodies based proprietary technology. The company provides monoclonal antibodies treatment for various diseases. It’s lead product Xilonix, a therapeutic antibody being developed for the treatment of metastatic colorectal cancer. XBiotech offers clinical trial activity services, oncology, MRSA, and dermatology related solutions. The company develops a True Human technology to discover and develop targeted antibody candidates. It pipeline includes candidates, which target various therapeutic areas such as pyoderma gangrenosum, plaque psoriasis, influenza and Type II diabetes, among others. It has operations in the US, Switzerland, Japan and Germany. XBiotech is headquartered in Austin, Texas, the US.

XBiotech Inc (XBIT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XBiotech Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11
Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12
Xbiotech Enters into Agreement with NCIC Clinical Trials 13
Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14
Licensing Agreements 15
XBiotech Enters into Licensing Agreement with CT Atlantic 15
Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16
Xbiotech Enters Into Licensing Agreement With Lonza Sales 17
XBiotech Enters Into Licensing Agreement With Strox Biopharma 18
Equity Offering 19
Xbiotech Raises USD31.8 Million in Public Offering of Shares 19
XBiotech Raises USD1 Million in Public Offering of Shares 20
XBiotech Raises USD1.8 Million in Public Offering of Shares 21
Xbiotech Raises USD76 Million in IPO 22
XBiotech Inc – Key Competitors 23
XBiotech Inc – Key Employees 24
XBiotech Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Sep 12, 2018: XBiotech appoints Dr. Peter Libby to its Scientific Advisory Board 26
Apr 10, 2017: XBiotech Announces Additions To Its Scientific Advisory Board 27
Product News 29
11/14/2017: XBiotech Announces Presentation of Novel Findings for MABp1 in the Prevention of Coronary Thrombosis at the American Heart Association Scientific Sessions 29
11/03/2017: XBiotech’s MABp1 to be Featured in Oral Presentation at the American Heart Association Scientific Sessions 30
10/03/2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board 31
09/20/2018: XBiotech announces addition of top dermatologist and researcher Dr. Alice Gottlieb to its team 32
09/15/2017: Refusal of the marketing authorisation for Human IgG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech 33
09/13/2018: XBiotech Announces Completion and Positive Interim Findings for Initial Cohort in Bermekimab Pilot Study in Atopic Dermatitis 34
08/27/2018: Xbiotech announces publication of breakthrough findings for potential role of interleukin-1 alpha in risk for heart attacks 35
06/08/2017: EMA Adopts a Negative Opinion for Human IgG1 mAb Specific for Human Interleukin-1 Alpha XBiotech 36
Product Approvals 37
Apr 20, 2017: XBiotech Announces Outcome of EMA’s Oral Explanation Meeting 37
Clinical Trials 38
Sep 24, 2018: XBiotech Announces Completion of U.S. Enrollment in Phase 2 Multicenter Study Evaluating Bermekimab in Patients with Hidradenitis Suppurativa 38
Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa 39
May 22, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic Dermatitis 40
Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology 41
Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 42
Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 43
Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology 44
Oct 18, 2017: XBiotech Announces First Patient in Study Evaluating MABp1 in Combination with Onivyde and 5-fluorouracil/folinic acid for the Treatment of Pancreatic Cancer 45
Sep 07, 2017: XBiotech Announces Presentation of Phase 2 Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa 46
Jun 09, 2017: XBiotech Announces Discontinuation of Phase III Study for Colorectal Cancer Based on Second Interim Analysis 47
Jun 01, 2017: XBiotech Presents Phase III Findings for its Antibody Therapy for Colorectal Cancer at the 2017 ASCO Meeting 48
May 30, 2017: Dr. Razelle Kurzrock to Present Novel Biomarker Findings from XBiotech Phase III Colorectal Cancer Study Data at the 19th European Society for Medical Oncology World Congress on Gastrointestinal Cancer 49
Feb 22, 2017: XBiotech Completes Dosing of Subjects in PK Study Being Conducted in Connection with European Marketing Application 50
Feb 21, 2017: Xbiotech Reports Affirmative Interim Analysis Of Global Phase 3 Colorectal Cancer Study 51
Feb 16, 2017: XBiotech Meets Primary Endpoint in Phase 2 Study of MABp1 for Treatment of Hidradenitis Suppurativa 52
Jan 17, 2017: XBiotech Phase 3 Data for Colorectal Cancer Therapy is Published in The Lancet Oncology 53
Other Significant Developments 54
Aug 10, 2018: XBiotech Highlights Quarterly Developments 54
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
XBiotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XBiotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XBiotech Inc, Deals By Therapy Area, 2012 to YTD 2018 9
XBiotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XBiotech Enters into Agreement with Cedars-Sinai Medical Center 11
Xbiotech Enters into Research Agreement with Case Western Reserve University School of Medicine 12
Xbiotech Enters into Agreement with NCIC Clinical Trials 13
Xbiotech Enters into Research Agreement with South Texas Blood & Tissue Center 14
XBiotech Enters into Licensing Agreement with CT Atlantic 15
Megapharm Enters into Licensing Agreement with XBiotech for Xilonix 16
Xbiotech Enters Into Licensing Agreement With Lonza Sales 17
XBiotech Enters Into Licensing Agreement With Strox Biopharma 18
Xbiotech Raises USD31.8 Million in Public Offering of Shares 19
XBiotech Raises USD1 Million in Public Offering of Shares 20
XBiotech Raises USD1.8 Million in Public Offering of Shares 21
Xbiotech Raises USD76 Million in IPO 22
XBiotech Inc, Key Competitors 23
XBiotech Inc, Key Employees 24
XBiotech Inc, Subsidiaries 25

List of Figures
XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XBiotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XBiotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[XBiotech Inc (XBIT)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • D. Western Therapeutics Institute Inc (4576)：製薬・医療：M&Aディール及び事業提携情報
    Summary D. Western Therapeutics Institute Inc (DWTI) is a pharmaceutical product s developer. The company offers ophthalmic solution, WP-1303, H-1337, K-134 and DW-1002. It discovers and develops drugs for glaucoma. DWTI’s ophthalmic solution treats glaucoma and ocular hypertension treatment and art …
  • Avis Budget Group, Inc.：戦略・SWOT・企業財務分析
    Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Avis Budget Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • SciBase AB (SCIB)：企業の財務・戦略的SWOT分析
    Summary SciBase AB (SciBase) is a medical technology company, which offers non-invasive detection and monitoring of skin tissue alterations. The company develops point of care device for the accurate detection of malignant melanoma. It offers electrical impedance spectroscopy which uses the varying …
  • Achema AB：企業の戦略的SWOT分析
    Achema AB - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. Th …
  • Hualan Biological Engineering Inc (002007)：企業の財務・戦略的SWOT分析
    Summary Hualan Biological Engineering Inc (Hualan Biological) is a biopharmaceutical company that develops vaccines. The company conducts research, develops and produces plasma, vaccines and gene products. Its plasma products include surgical lyophilized fibrin sealant, human coagulation factor VIII …
  • Eizo Corp (6737)：企業の財務・戦略的SWOT分析
    Eizo Corp (6737) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • EnviTec Biogas AG (ETG)：企業の財務・戦略的SWOT分析
    EnviTec Biogas AG (ETG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Credit Saison Co., Ltd.：企業の戦略・SWOT・財務情報
    Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Enercon Services Inc：企業の戦略的SWOT分析
    Enercon Services Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Delek US Holdings, Inc.：企業のM&A・事業提携・投資動向
    Delek US Holdings, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Delek US Holdings, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Venn Life Sciences Holdings Plc (VENN)：製薬・医療：M&Aディール及び事業提携情報
    Summary Venn Life Sciences Holdings Plc (Venn Life Sciences), formerly Armscote Investment Company Plc is a contract research organization that offers drug development, clinical trial management and resourcing solutions. The organization offers drug development services such as clinical pharmacology …
  • Ben E. Keith Company：戦略・SWOT・企業財務分析
    Ben E. Keith Company - Strategy, SWOT and Corporate Finance Report Summary Ben E. Keith Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Goodman Fielder Pty Ltd：企業の戦略・SWOT・財務情報
    Goodman Fielder Pty Ltd - Strategy, SWOT and Corporate Finance Report Summary Goodman Fielder Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Coherent Inc (COHR)：企業の財務・戦略的SWOT分析
    Coherent Inc (COHR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Applied Industrial Technologies, Inc.：企業のM&A・事業提携・投資動向
    Applied Industrial Technologies, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Applied Industrial Technologies, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed report …
  • Bridgestone Corporation：企業の戦略・SWOT・財務情報
    Bridgestone Corporation - Strategy, SWOT and Corporate Finance Report Summary Bridgestone Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Famy Care Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Famy Care Ltd (Famy Care) is a healthcare products provider that research, develops and manufactures female reproductive health care products. The company manufactures hormonal and reproductive health care products including famy care. Its hormonal formulation products include combined oral …
  • Tauron Polska Energia SA (TPE)：電力：M&Aディール及び事業提携情報
    Summary Tauron Polska Energia S.A. (Tauron), formerly Energetyka Poludnie S.A., is an electric utility company. The group through its subsidiaries and joint ventures carries out business activities including coal mining, generation, distribution and supply of electricity and heat. Tauron generates e …
  • HOB Biotech Group Suzhou Co Ltd：医療機器：M&Aディール及び事業提携情報
    Summary HOB Biotech Group Suzhou Co Ltd (HOB Biotech) is a manufacturer of allergy and autoimmune in vitro diagnostics. It owns and operates bioclia, bioline, and biolisa. The company’s bioclia is engaged in cutting-edge nanoparticle and chemiluminescent technology, and chemiluminescent immuno assay …
  • Japan Tobacco Inc.：企業の戦略・SWOT・財務分析
    Japan Tobacco Inc. - Strategy, SWOT and Corporate Finance Report Summary Japan Tobacco Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆